α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571

Blood

Volumn 99, Issue 2, 2002, Pages 713-715

  Jørgensen, Heather G ^a,b   Elliott, Moira A ^a,b   Allan, Elaine K ^a,b   Carr, Christine E ^a,b   Holyoake, Tessa L ^a,b   Smith, Kevin D ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; OROSOMUCOID; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; DRUG ANTAGONISM; DRUG RESISTANCE; METABOLISM; MYELOID LEUKEMIA; PHYSIOLOGY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NEOPLASM PROTEINS; OROSOMUCOID; PIPERAZINES; PYRIMIDINES;

EID: 0345405480     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.2.713     Document Type: Article

References (17)

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
2. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
3. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
4. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
5. + leukemia patients treated with an abl-specific kinase inhibitor is associated with reactivation of BCR-ABL
6. Bcr/abl gene amplification: A possible mechanism of drug resistance in patients treated with an abl-specific kinase inhibitor
7. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation
8. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health
9. Changes in glycosylation of acute phase proteins in health and disease: Occurrence, regulation and function
10. The heterogeneity of alpha-1-acid glycoprotein in rheumatoid arthritis
11. Drug binding sites on human alpha-1-acid glycoprotein
12. Binding of drugs to alpha-1-acid glycoprotein and its desialylated form: Influence on hepatic disposition and implications for drug targeting to the liver
13. + leukemic cells to the Abl inhibitor STI571
14. The non-degradative isolation of alpha-1-acid glycoprotein from normal and rheumatoid plasma
15. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
16. Development of largescale fractionation methods, IV: A simple method for the large-scale preparation of α1-acid glycoprotein
17. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification